Publications by authors named "Emile D Kerver"

Claim this Profile
D
Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOPANC-1 and -2 trials.
Bo T M Strijbos, Imme Kraakman, Jana S Hopstaken, Jelle C van Dongen, Quisette P Janssen, Emile D Kerver

Br J Surg· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer.
Marjolein F Lansbergen, Mark P G Dings, Jan Koster, Mariette Labots, Emile D Kerver

Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.
Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk, Emile D Kerver

JAMA Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, Jade M van Berge Henegouwen, Gijs F de Wit, Emile D Kerver

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Ilse A C Spiekman, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk, Soemeya F Haj Mohammad, Emile D Kerver

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of the corrected count increment after platelet transfusion, a secondary analysis of the PACER randomized controlled trial.
Floor L F van Baarle, Emma K van de Weerdt, Walter J F M van der Velden, Roelof A Ruiterkamp, Pieter R Tuinman, Emile D Kerver

Am J Hematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk, Emile D Kerver

Lancet Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia.
Floor L F van Baarle, Emma K van de Weerdt, Walter J F M van der Velden, Roelof A Ruiterkamp, Pieter R Tuinman, Emile D Kerver

N Engl J Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Birgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, Laurien J Zeverijn, Gijs F de Wit, Emile D Kerver

BMC Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Louisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J Zeverijn, Daphne L van der Velden, Emile D Kerver

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Eva Versteijne, Jacob L van Dam, Mustafa Suker, Quisette P Janssen, Karin Groothuis, Emile D Kerver

J Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.
Joost S Vermaat, Sebastiaan F Somers, Liesbeth C de Wreede, Willem Kraan, Ruben A L de Groen, Emile D Kerver

Haematologica· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Marieke S Walma, Lilly J Brada, Susana I S Patuleia, Joost G Blomjous, Thomas L Bollen, Emile D Kerver

Eur J Surg Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
G Emerens Wensink, Marloes A G Elferink, Anne M May, Linda Mol, Patricia A H Hamers, Emile D Kerver

Br J Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Eva Versteijne, Mustafa Suker, Karin Groothuis, Janine M Akkermans-Vogelaar, Marc G Besselink, Emile D Kerver

J Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Sushil K Badrising, Vincent van der Noort, Paul Hamberg, Jules L L M Coenen, Maureen J Aarts, Emile D Kerver

Oncology· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Sushil K Badrising, Vincent van der Noort, Alfons J M van den Eertwegh, Paul Hamberg, Inge M van Oort, Emile D Kerver

Prostate· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Sushil Badrising, Vincent van der Noort, Inge M van Oort, H Pieter van den Berg, Maartje Los, Emile D Kerver

Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis